CN118141946A - 一种聚集诱导发光工程线粒体的制备方法 - Google Patents
一种聚集诱导发光工程线粒体的制备方法 Download PDFInfo
- Publication number
- CN118141946A CN118141946A CN202211557833.9A CN202211557833A CN118141946A CN 118141946 A CN118141946 A CN 118141946A CN 202211557833 A CN202211557833 A CN 202211557833A CN 118141946 A CN118141946 A CN 118141946A
- Authority
- CN
- China
- Prior art keywords
- aggregation
- induced emission
- mitochondria
- engineering
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002776 aggregation Effects 0.000 title claims abstract description 48
- 238000004220 aggregation Methods 0.000 title claims abstract description 48
- 210000003470 mitochondria Anatomy 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 239000000463 material Substances 0.000 claims abstract description 29
- 238000003756 stirring Methods 0.000 claims abstract description 7
- 238000001914 filtration Methods 0.000 claims abstract description 4
- 238000009210 therapy by ultrasound Methods 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 12
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 10
- DMBHHRLKUKUOEG-UHFFFAOYSA-N diphenylamine Chemical compound C=1C=CC=CC=1NC1=CC=CC=C1 DMBHHRLKUKUOEG-UHFFFAOYSA-N 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 7
- 239000006166 lysate Substances 0.000 claims description 7
- 230000002438 mitochondrial effect Effects 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- 239000006285 cell suspension Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- ZFAGSDJDJKIGEV-UHFFFAOYSA-N 1,4-dimethyl-2H-pyridine hydroiodide Chemical compound I.CN1CC=C(C)C=C1 ZFAGSDJDJKIGEV-UHFFFAOYSA-N 0.000 claims description 4
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- 210000001700 mitochondrial membrane Anatomy 0.000 abstract description 5
- 239000002086 nanomaterial Substances 0.000 abstract description 5
- 230000009471 action Effects 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000000302 molecular modelling Methods 0.000 description 2
- YOBTXORLVXZWSR-UHFFFAOYSA-M 1,4-dimethylpyridin-1-ium;iodide Chemical compound [I-].CC1=CC=[N+](C)C=C1 YOBTXORLVXZWSR-UHFFFAOYSA-M 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Materials Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了一种聚集诱导发光工程线粒体的制备方法，把制备好的聚集诱导发光材料AIEgen与线粒体孵育在PBS溶液中，超声，搅拌，AIEgen会在分子作用力下自动与线粒体膜产生分子作用并最终结合在膜上，之后过滤，离心后即可以得到所述聚集诱导发光工程线粒体。该工程线粒体用于治疗疾病，为利用纳米材料工程化的线粒体治疗疾病提供了更多可能性。
Description
技术领域
本发明涉及聚集诱导发光材料领域，特别涉及一种聚集诱导发光工程线粒体的制备方法。
背景技术
在应用纳米材料的治疗中，在很多情况中运用线粒体将材料带入细胞从而产生治疗作用往往比直接注入材料效果更好，这就需要去分离线粒体，实现线粒体的工程化和多功能线粒体的制备。
在纳米材料癌症治疗中，不合适的材料会造成严重的副作用，如具有高生物毒性的金属离子和高浓度的材料。因此，应用一个有低副作用同时保证治疗效果的材料是治疗的基础。聚集诱导发光材料(AIEgen)就有着低副作用和高效产生活性氧并杀死癌细胞的作用，使其成为了制备聚集诱导发光工程的线粒体时的理想材料。而且，在很多情况下直接注入纳米材料的治疗效果并没有通过与线粒体或其它细胞器结合并被带入细胞的治疗效果要好。刘晶晶等人成功合成了脂质共轭的聚集诱导发光材料并让它和线粒体膜通过疏水作用结合，最终制成了与脂质共轭的聚集诱导发光材料结合的工程线粒体，她们对所制成的线粒体进行了物理性能的分析，包括拍摄透射电镜的照片，进一步证明了结合的成功。不仅如此，当她们用这种线粒体于光动力治疗癌症时，效果很好，体现了这种合成线粒体的应用价值。但是其制备过程过于繁琐。因此目前亟需一种步骤简单便于工业化生产的聚集诱导发光工程线粒体的制备方法。
发明内容
针对现有技术中的缺陷，本发明提出了一种聚集诱导发光工程线粒体的制备方法。步骤相对简单而且容易上手，可以大量高效生产。
本发明提供一种聚集诱导发光工程线粒体的制备方法，包括如下步骤：
S1：7-(二苯胺)-9-乙基-9H-(咔唑)-2-碳醛溶液在乙醇中加入1,4-二甲基碘化吡啶和哌啶，室温下回流3小时；当冷却到室温时，产品收集，洗涤，冷冻干燥，得到红色碘盐固体；
S2：用丙酮溶解所述红色碘盐固体，滴加六氟磷酸钾溶液；将制备好的混合物进一步充分搅拌纯化得到聚集诱导发光材料；
S3：将所述聚集诱导发光材料和线粒体裂解液与PBS溶液充分混合，超声，搅拌；把多余的细胞悬液过滤进入微孔管，离心，洗涤沉淀，得到聚集诱导发光工程线粒体。
进一步的，所述步骤S1中所述7-(二苯胺)-9-乙基-9H-(咔唑)-2-碳醛溶液的浓度为1.28mmol,用量为0.5g。
进一步的，所述步骤S1中所述乙醇的用量为15mL；所述1,4-二甲基碘化吡啶的浓度为1.16mmol,用量为0.27g。
进一步的，所述步骤S1中所述哌啶的用量为1滴；回流时间为3小时。洗涤次数为3次。
进一步的，所述步骤S1中得到的红色碘盐固体质量为0.56g，纯度为80％。
进一步的，所述步骤S2中所述六氟磷酸钾的用量为20mL。
进一步的，所述步骤S2中得到的聚集诱导发光材料的质量为0.57g，纯度为99％。
进一步的，所述步骤S3中所述聚集诱导发光材料的浓度为0.01～10mg/mL，所述线粒体裂解液的浓度为200μg/mL。
进一步的，所述步骤S3中所述聚集诱导发光材料与所述线粒体裂解液的负载比为1:9,w/w。
本发明还提供一种聚集诱导发光工程线粒体，由所述的制备方法制备得到。
综上，与现有技术相比，本发明达到了以下技术效果：
本发明通过简单的混合自制的聚集诱导发光材料和线粒体开发了聚集诱导发光工程线粒体，步骤相对简单而且容易上手，可以大量高效生产。在之后的生物实验中，本发明的聚集诱导发光工程线粒体制备方法具有控制普适性强，生产过程中绿色环保，化学助剂无污染，便于工业化生产等优点。本发明提供的聚集诱导发光工程线粒体，把纳米材料带入体内的效果好，生物毒性小，治疗效果好；应用领域不局限于传统的某一特定领域，在生物医疗等行业具有广泛的应用，使得它在体内疾病治疗有很大潜力。
附图说明
为了更清楚地说明本发明实施例的技术方案，下面将对实施例中所需要使用的附图作简单地介绍，应当理解，以下附图仅示出了本发明的某些实施例，因此不应被看作是对范围的限定，对于本领域普通技术人员来讲，在不付出创造性劳动的前提下，还可以根据这些附图获得其他相关的附图。
图1为本发明的聚集诱导发光材料修饰前后(前：A；后：B)线粒体的透射电子显微镜图像。
图2为DCPy与线粒体膜结合的分子模拟图。
图3为聚集诱导发光工程的线粒体的制备以及它在微波动力治疗癌症中的应用。
具体实施方式
为了使本技术领域的人员更好地理解本发明方案，下面将结合本发明实施例中的附图，对本发明实施例中的技术方案进行清楚、完整地描述，显然，所描述的实施例仅仅是本发明一部分的实施例，而不是全部的实施例。基于本发明中的实施例，本领域普通技术人员在没有做出创造性劳动的前提下所获得的所有其他实施例，都应当属于本发明保护的范围。
本发明实现了聚集诱导发光工程的线粒体的成功制备。通过对于类似文献的研究，设计了一种新的制备聚集诱导发光工程的线粒体的方法：把提前制备好的聚集诱导发光材料AIEgen与线粒体孵育在PBS溶液中，超声，搅拌，AIEgen会在分子作用力下自动与线粒体膜产生分子作用并最终结合在膜上，之后过滤，离心后即可以得到想要的聚集诱导发光工程的线粒体。
实施例1
本发明的聚集诱导发光工程的线粒体的制备方法具体如下：
7-(二苯胺)-9-乙基-9H-(咔唑)-2-碳醛(1.28mmol,0.5g)溶液在15mL乙醇中加入1,4-二甲基碘化吡啶(1.16mmol,0.27g)和哌啶(1滴)在室温下回流3小时。当冷却到室温时，产品收集，洗涤3次，冷冻干燥，得到红色碘盐固体(80％，0.56g)，用丙酮溶解固体产物，滴加20mL KPF6溶液。将制备好的混合物进一步充分搅拌25分钟纯化得到最终产物DCPy(99％，0.57g)，也就是聚集诱导发光材料。将0.01～10mg/mL的DCPy和200μg/mL的线粒体裂解液与PBS溶液充分混合，超声10min，搅拌1h。把多余的细胞悬液过滤进入微孔管(MWCO100kDa；)，3500rpm离心20min，得到的沉淀洗涤几次，这就是想要的聚集诱导发光工程的线粒体。通过紫外吸收测定，确定DCPy与线粒体的最佳负载比为1:9,w/w。
实施例2
分别用分子模拟(图2)和透射电子显微镜图像(图1)证明了聚集诱导发光材料在本发明的方法下的确与线粒体结合了。成功用体外线粒体和聚集诱导发光材料成功合成了聚集诱导发光工程的线粒体并应用于小鼠癌症的微波治疗中。治疗效果与单独注射聚集诱导发光材料相比更加显著，显示了本发明的聚集诱导发光工程的线粒体在微波治疗癌症中的优点。
以上所述仅为本发明的较佳实施例，并不用以限制本发明，凡在本发明的精神和原则之内，所作的任何修改、等同替换、改进等，均应包含在本发明的保护范围之内。
Claims (10)
1.一种聚集诱导发光工程线粒体的制备方法，其特征在于，包括如下步骤：
S1：7-(二苯胺)-9-乙基-9H-(咔唑)-2-碳醛溶液在乙醇中加入1,4-二甲基碘化吡啶和哌啶，室温下回流3小时；当冷却到室温时，产品收集，洗涤，冷冻干燥，得到红色碘盐固体；
S2：用丙酮溶解所述红色碘盐固体，滴加六氟磷酸钾溶液；将制备好的混合物进一步充分搅拌纯化得到聚集诱导发光材料；
S3：将所述聚集诱导发光材料和线粒体裂解液与PBS溶液充分混合，超声，搅拌；把多余的细胞悬液过滤进入微孔管，离心，洗涤沉淀，得到聚集诱导发光工程线粒体。
2.根据权利要求1所述的制备方法，其特征在于，所述步骤S1中所述7-(二苯胺)-9-乙基-9H-(咔唑)-2-碳醛溶液的浓度为1.28mmol,用量为0.5g。
3.根据权利要求1所述的制备方法，其特征在于，所述步骤S1中所述乙醇的用量为15mL；所述1,4-二甲基碘化吡啶的浓度为1.16mmol,用量为0.27g。
4.根据权利要求1所述的制备方法，其特征在于，所述步骤S1中所述哌啶的用量为1滴；回流时间为3小时。洗涤次数为3次。
5.根据权利要求1所述的制备方法，其特征在于，所述步骤S1中得到的红色碘盐固体质量为0.56g，纯度为80％。
6.根据权利要求1所述的制备方法，其特征在于，所述步骤S2中所述六氟磷酸钾的用量为20mL。
7.根据权利要求1所述的制备方法，其特征在于，所述步骤S2中得到的聚集诱导发光材料的质量为0.57g，纯度为99％。
8.根据权利要求1所述的制备方法，其特征在于，所述步骤S3中所述聚集诱导发光材料的浓度为0.01～10mg/mL，所述线粒体裂解液的浓度为200μg/mL。
9.根据权利要求1所述的制备方法，其特征在于，所述步骤S3中所述聚集诱导发光材料与所述线粒体裂解液的负载比为1:9,w/w。
10.一种聚集诱导发光工程线粒体，其特征在于，由权利要求1-9任一项所述的制备方法制备得到。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211557833.9A CN118141946A (zh) | 2022-12-06 | 2022-12-06 | 一种聚集诱导发光工程线粒体的制备方法 |
| PCT/CN2022/138815 WO2024119530A1 (zh) | 2022-12-06 | 2022-12-13 | 一种聚集诱导发光工程线粒体的制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211557833.9A CN118141946A (zh) | 2022-12-06 | 2022-12-06 | 一种聚集诱导发光工程线粒体的制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118141946A true CN118141946A (zh) | 2024-06-07 |
Family
ID=91297586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211557833.9A Pending CN118141946A (zh) | 2022-12-06 | 2022-12-06 | 一种聚集诱导发光工程线粒体的制备方法 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN118141946A (zh) |
| WO (1) | WO2024119530A1 (zh) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030044776A1 (en) * | 1998-09-25 | 2003-03-06 | James A. Dykens | Compositions and methods for identifying agents that alter mitochondrial permeability transition pores |
| CN110407736B (zh) * | 2018-04-27 | 2022-10-21 | 香港科技大学 | 具有强双光子吸收的近红外化合物的制备及应用 |
| WO2020164448A1 (en) * | 2019-02-12 | 2020-08-20 | The Hong Kong University Of Science And Technology | Fluorescent Probes for Singlet Oxygen Generation and Cancer Ablation |
| CN114349736B (zh) * | 2020-10-13 | 2024-08-13 | 香港科技大学 | 一种化合物及其应用 |
| CN113975391B (zh) * | 2021-10-27 | 2023-04-07 | 深圳先进技术研究院 | 一种自供氧光敏剂及其制备方法和应用 |
| CN115109052B (zh) * | 2022-07-13 | 2023-08-22 | 南京师范大学 | 一种具有线粒体靶向的aie化合物及其合成方法和应用 |
-
2022
- 2022-12-06 CN CN202211557833.9A patent/CN118141946A/zh active Pending
- 2022-12-13 WO PCT/CN2022/138815 patent/WO2024119530A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024119530A1 (zh) | 2024-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2015188570A1 (zh) | 一种白蛋白吲哚菁绿紫杉醇复合物及其制备方法与应用 | |
| CN102258471B (zh) | 一种基于磺化杯[4]芳烃的纳米超分子囊泡制备及应用 | |
| CN111603559B (zh) | 铜碘簇化合物@光敏剂复合纳米颗粒及其作为x射线光动力治疗药物的应用 | |
| CN109207143B (zh) | 一种功能化修饰的荧光碳量子点及其制备方法和应用 | |
| Zhou et al. | Gel systems doped with chiral carbon dots for optical combination | |
| CN103497347B (zh) | 一种双功能壳聚糖微球的制备方法 | |
| CN107099287B (zh) | 一种用作可见光催化光敏剂碳量子点的水热制备方法 | |
| CN113262300A (zh) | 一种用于线粒体靶向递送光敏剂pcn-224的纳米粒子及制备方法、应用 | |
| Saheeda et al. | Investigation on the pH‐independent photoluminescence emission from carbon dots impregnated on polymer matrix | |
| Chen et al. | Ultrasmall MnSe Nanoparticles as T 1-MRI Contrast Agents for In Vivo Tumor Imaging | |
| CN109894082B (zh) | 一种纳米花型共价有机框架复合材料的制备方法和应用 | |
| CN118141946A (zh) | 一种聚集诱导发光工程线粒体的制备方法 | |
| Kirbas Cilingir et al. | Small Warriors of Nature: Novel Red Emissive Chlorophyllin Carbon Dots Harnessing Fenton‐Fueled Ferroptosis for In Vitro and In Vivo Cancer Treatment | |
| WO2024046032A1 (zh) | 基于非天然氨基酸的离子液体、其制备方法及应用 | |
| CN107970224B (zh) | 一种脂质修饰磁性氧化石墨烯复合材料的制备方法及应用 | |
| WO2015156385A1 (ja) | ホウ素化合物を内包および外壁に担持するカーボンナノホーン及びその製造方法 | |
| CN105420278A (zh) | 采用光致穿孔的方式制备负载有外源分子细胞的方法及制备该细胞用的基材及该细胞 | |
| CN110857335A (zh) | 二维金属-有机骨架结构纳米片及其制备方法与应用 | |
| Dong et al. | A zeolite-based ship-in-a-bottle route to ultrasmall carbon dots for live cell labeling and bioimaging | |
| CN103320471B (zh) | 一种非病毒基因载体及其制备方法 | |
| CN113735099B (zh) | 一种电子转移复合物和表面羟基协同稳定的富勒烯/水原液的制备方法 | |
| CN113278416B (zh) | 水溶性柱芳烃修饰的两亲性石墨烯量子点、制备方法及应用 | |
| JP2012188362A (ja) | 金属ナノロッド複合体およびその製造方法 | |
| CN110591107B (zh) | 基于二聚叔醇的超分子有机框架材料的纳米晶体及其制备方法和应用 | |
| CN111203546B (zh) | 一种十六聚体铁蛋白-金纳米簇及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |